Arkolith/Insider Trading/IGC/Form 4

Mukunda Ram

CEO, DirectorIGC Pharma, Inc. (IGC) · full profile →Form 4 · filed Feb 4, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 3, 2026Option exercise(M)50K—$0861K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 3, 2026Grant(A)17K—$017K
Feb 3, 2026Grant(A)67K—$067K

Transaction Codes

M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001185185-26-000411) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML